PE20110066A1 - Dronedarona para la prevencion de la cardioversion - Google Patents

Dronedarona para la prevencion de la cardioversion

Info

Publication number
PE20110066A1
PE20110066A1 PE2010001116A PE2010001116A PE20110066A1 PE 20110066 A1 PE20110066 A1 PE 20110066A1 PE 2010001116 A PE2010001116 A PE 2010001116A PE 2010001116 A PE2010001116 A PE 2010001116A PE 20110066 A1 PE20110066 A1 PE 20110066A1
Authority
PE
Peru
Prior art keywords
prevention
hazardous
dronedarone
cardioversion
accidental
Prior art date
Application number
PE2010001116A
Other languages
English (en)
Inventor
Christophe Gaudin
Nacera Hamdani
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739955&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20110066A1 publication Critical patent/PE20110066A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Furan Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UN MEDICAMENTO QUE CONTIENE DRONEDARONA, EL CUAL ES UTIL EN LA PREVENCION DE LA CARDIOVERSION ELECTRICA DE PACIENTES QUE TIENEN UN HISTORIAL DE FIBRILACION AURICULAR O ALETEO AURICULAR Y QUE ADEMAS PRESENTAN AL MENOS UN FACTOR DE RIESGO COMO HIPERTENSION, DIABETES, ACCIDENTE CEREBROVASCULAR O EMBOLISMO SISTEMICO PREVIO, ENFERMEDAD CARDIACA CORONARIA, ENTRE OTROS, O AL MENOS UN DISPOSITIVO CARDIACO COMO UN ESTIMULADOR CARDIACO O UN DESFIBRILADOR CARDIOVERTER IMPLANTABLE. DONDE LA DOSIS DIARIA DE DRONEDARONA PUEDE ALCANZAR 800MG.
PE2010001116A 2008-06-10 2009-06-08 Dronedarona para la prevencion de la cardioversion PE20110066A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6026008P 2008-06-10 2008-06-10
EP08290532A EP2133075A1 (en) 2008-06-10 2008-06-10 Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion

Publications (1)

Publication Number Publication Date
PE20110066A1 true PE20110066A1 (es) 2011-02-16

Family

ID=39739955

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001116A PE20110066A1 (es) 2008-06-10 2009-06-08 Dronedarona para la prevencion de la cardioversion

Country Status (25)

Country Link
US (1) US20110166221A1 (es)
EP (2) EP2133075A1 (es)
JP (1) JP2011522875A (es)
KR (1) KR20110026421A (es)
CN (1) CN102056602A (es)
AR (1) AR072070A1 (es)
AU (1) AU2009259008A1 (es)
BR (1) BRPI0915015A2 (es)
CA (1) CA2727210A1 (es)
CL (1) CL2010001421A1 (es)
CO (1) CO6280478A2 (es)
CR (1) CR11755A (es)
DO (1) DOP2010000361A (es)
EA (1) EA201071412A1 (es)
EC (1) ECSP10010661A (es)
IL (1) IL209790A0 (es)
MA (1) MA32461B1 (es)
MX (1) MX2010013700A (es)
NI (1) NI201000212A (es)
PE (1) PE20110066A1 (es)
SV (1) SV2010003753A (es)
TW (1) TW201002314A (es)
UY (1) UY31887A (es)
WO (1) WO2009150534A1 (es)
ZA (1) ZA201009171B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
PE20091809A1 (es) 2008-04-17 2009-12-03 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
CN104721547A (zh) * 2015-03-14 2015-06-24 包汉雨 一种促进房颤患者复律的中药组合物

Also Published As

Publication number Publication date
TW201002314A (en) 2010-01-16
EP2303259A1 (en) 2011-04-06
CN102056602A (zh) 2011-05-11
DOP2010000361A (es) 2010-12-31
SV2010003753A (es) 2011-03-15
MX2010013700A (es) 2011-02-23
AR072070A1 (es) 2010-08-04
WO2009150534A1 (en) 2009-12-17
CL2010001421A1 (es) 2011-05-13
NI201000212A (es) 2011-04-27
CO6280478A2 (es) 2011-05-20
CA2727210A1 (en) 2009-12-17
ZA201009171B (en) 2012-03-28
UY31887A (es) 2010-01-29
EA201071412A1 (ru) 2011-06-30
ECSP10010661A (es) 2011-01-31
AU2009259008A1 (en) 2009-12-17
US20110166221A1 (en) 2011-07-07
CR11755A (es) 2011-01-10
IL209790A0 (en) 2011-02-28
MA32461B1 (fr) 2011-07-03
KR20110026421A (ko) 2011-03-15
JP2011522875A (ja) 2011-08-04
BRPI0915015A2 (pt) 2015-10-27
EP2133075A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
PE20110066A1 (es) Dronedarona para la prevencion de la cardioversion
CO2018006358A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter-defibrillators: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices
BR0007477A (pt) Aparelho e processo para regulagem elétrica de ritmo cardìaco
WO2006083617A3 (en) Cardiac harness having electrodes and epicardial leads
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2010033190A3 (en) Cardiac function management integrating cardiac contractility modulation
WO2010051425A3 (en) Implantable medical device crosstalk evaluation and mitigation
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
BRPI0417932A (pt) lipólise medicamentosa de acúmulo de gordura
WO2010028295A3 (en) Overlapping pacing and tachyarrhythmia detection zones
PH12015502655A1 (en) Method
Kanlop et al. Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine
Arumugam et al. A lethal injection?
ATE517657T1 (de) Aktive implantierbare medizinische vorrichtung, insbesondere herzschrittmacher, defibrillator, und/oder kardiovertierer aai oder aai/ddd mit erfassung von ventrikulären tachykardien
Indik et al. Direction of signal recording affects waveform characteristics of ventricular fibrillation in humans undergoing defibrillation testing during ICD implantation
Fradley Multiple cardiotoxic effects: case report
WO2013079048A3 (de) Implantierbare indifferente elektrode
Dariusz et al. The presence of pacing artifacts may impede diagnosis of ventricular fibrillation during cardiac arrest.
Rottenberg The need for separate analyses of survival for" in-home" arrests versus" out-of-home" arrests in the determination of whether it is best to shock first or perform 3 min of CPR before the first defibrillation; in patients with ventricular fibrillation cardiac arrest when the ambulance response time is greater than 5 min
Tien et al. Sudden Death of a Schizophrenic Patient with Spinal Cord Injury under Combination Antipsychotics
Ryu et al. ICD Technology
Israel et al. Advances in the treatment of atrial tachyarrhythmias: pacing, cardioversion, and defibrillation
Okreglicki ECG Quiz 28
Sloane et al. 101 Assessment of Stress Markers in Restrained Individuals Following Physical Stress With and Without a Sham TASER Activation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal